Pacific Shuanglin Bio-pharmacy Hits Day Low at CNY 12.15 Amid Price Pressure

Pacific Shuanglin Bio-pharmacy Co., Ltd. has experienced a notable decline today, with the stock dropping by 3.61% as of June 8, 2026. The stock reached an intraday low of CNY 12.15, reflecting ongoing challenges in its financial performance. Over the past year, the company has reported a significant decrease of 27.65%, contrasting sharply with the China Shanghai Composite, which has gained 16.95% during the same period. In terms of financial metrics, Pacific Shuanglin has faced a decline in net sales by 8.47%, marking a continuation of negative results for six consecutive quarters. The company’s operating cash flow has also reached a low of CNY -201.95 million, indicating liquidity concerns. Additionally, the return on capital employed (ROCE) stands at a low 4.38%, further highlighting the company's struggles. Despite a modest increase of 4.78% over the past month, the long-term outlook remains concerning, with the stock showing a decline of 63.68% over the last five years. As a large-cap player in the pharmaceuticals and biotechnology sector, Pacific Shuanglin's current performance metrics suggest a challenging environment ahead.